Analysts predict that Eagle Pharmaceuticals Inc (NASDAQ:EGRX) will announce sales of $58.60 million for the current quarter, according to Zacks. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The lowest sales estimate is $57.30 million and the highest is $59.90 million. Eagle Pharmaceuticals posted sales of $63.02 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 7%. The firm is expected to issue its next quarterly earnings results on Wednesday, November 14th.
According to Zacks, analysts expect that Eagle Pharmaceuticals will report full-year sales of $227.00 million for the current financial year, with estimates ranging from $225.90 million to $228.10 million. For the next financial year, analysts anticipate that the company will post sales of $259.80 million, with estimates ranging from $243.90 million to $275.70 million. Zacks’ sales averages are an average based on a survey of research firms that cover Eagle Pharmaceuticals.
Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Tuesday, August 7th. The specialty pharmaceutical company reported $0.95 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.15. Eagle Pharmaceuticals had a return on equity of 19.71% and a net margin of 13.81%. The firm had revenue of $59.30 million for the quarter, compared to analyst estimates of $51.78 million.
A number of brokerages recently weighed in on EGRX. Mizuho raised Eagle Pharmaceuticals from an “underperform” rating to a “neutral” rating in a report on Monday, June 11th. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, September 29th. Royal Bank of Canada set a $84.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, August 8th. Piper Jaffray Companies set a $88.00 price objective on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, August 7th. Finally, Zacks Investment Research lowered Eagle Pharmaceuticals from a “strong-buy” rating to a “sell” rating in a report on Tuesday, September 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $86.50.
EGRX stock traded down $2.30 on Thursday, reaching $65.15. 147,832 shares of the company’s stock were exchanged, compared to its average volume of 235,499. Eagle Pharmaceuticals has a twelve month low of $48.84 and a twelve month high of $85.66. The firm has a market capitalization of $1.04 billion, a PE ratio of 19.33 and a beta of 1.32. The company has a debt-to-equity ratio of 0.22, a current ratio of 4.22 and a quick ratio of 4.09.
A number of institutional investors have recently bought and sold shares of EGRX. Rothschild Asset Management Inc. acquired a new stake in Eagle Pharmaceuticals in the second quarter valued at $30,835,000. BlackRock Inc. grew its holdings in Eagle Pharmaceuticals by 14.7% in the second quarter. BlackRock Inc. now owns 1,432,090 shares of the specialty pharmaceutical company’s stock valued at $108,351,000 after purchasing an additional 183,287 shares during the last quarter. Chartwell Investment Partners LLC acquired a new stake in Eagle Pharmaceuticals in the second quarter valued at $12,063,000. Granite Investment Partners LLC grew its holdings in Eagle Pharmaceuticals by 74.0% in the second quarter. Granite Investment Partners LLC now owns 198,774 shares of the specialty pharmaceutical company’s stock valued at $15,039,000 after purchasing an additional 84,567 shares during the last quarter. Finally, Sei Investments Co. grew its holdings in Eagle Pharmaceuticals by 236.9% in the second quarter. Sei Investments Co. now owns 112,279 shares of the specialty pharmaceutical company’s stock valued at $8,495,000 after purchasing an additional 78,953 shares during the last quarter.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).
Recommended Story: Conference Calls
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.